Full Breakdown
Eli Lilly Acquires Orna Therapeutics to Advance In Vivo CAR-T Therapies
2/10/2026, 5:22:40 PM
Acquisition Overview
On February 9, 2026, Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Orna Therapeutics, a biotechnology firm specializing in engineered circular RNA (oRNA) and lipid nanoparticle (LNP) technologies. The acquisition is valued at up to $2.4 billion, which includes an upfront payment and additional milestone payments contingent on clinical development achievements. This strategic move aims to enhance Lilly's capabilities in developing innovative therapies for autoimmune diseases.
Orna Therapeutics and Its Technology
Orna Therapeutics, founded in 2021, focuses on creating in vivo cell therapies that allow patients' bodies to generate their own therapeutic cells. Its lead program, ORN-252, is a clinical trial-ready Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting CD19, a protein prevalent on B cells involved in autoimmune disorders. The use of circular RNA is expected to provide more durable therapeutic protein expression compared to traditional linear mRNA approaches, potentially revolutionizing treatment options for conditions like lupus and other B cell-driven autoimmune diseases.
Implications of the Acquisition
The acquisition of Orna strengthens Lilly's position in the competitive field of immunology, particularly in developing next-generation CAR-T therapies that are easier and more cost-effective to manufacture. Traditional CAR-T therapies require complex procedures involving the extraction and genetic modification of a patient’s cells, which can be logistically challenging. In contrast, Orna's technology aims to simplify this process by enabling in vivo modifications, thereby broadening access to these innovative treatments.
Official Statements & Responses
Francisco Ramírez-Valle, M.D., Ph.D., Senior Vice President at Lilly, emphasized the potential of Orna's technology to unlock new treatment avenues for patients with limited options. He stated, “Early autologous CAR-T studies have shown the promise of cell therapy for patients with autoimmune diseases, but the complexity, cost, and logistics of ex vivo approaches make it challenging to deliver these breakthroughs to the broader population of patients who need them.” Joe Bolen, Ph.D., CEO of Orna, expressed excitement about the partnership, noting that their technology could significantly impact patient care.
Criticism & Opposition
While the acquisition is seen as a positive step for Lilly, some analysts caution about the inherent risks associated with drug development and commercialization. Concerns have been raised regarding the feasibility of achieving the expected benefits from the acquisition, given the uncertainties in clinical trials and market acceptance of new therapies.
What's Next
Following the acquisition, Lilly plans to integrate Orna's technology into its existing pipeline, which includes other in vivo therapies. The company aims to leverage this acquisition to expand its offerings in the autoimmune disease space, potentially leading to new treatments that could reshape patient care in this area.
In summary, Eli Lilly's acquisition of Orna Therapeutics represents a significant advancement in the field of cell therapy, with the potential to transform treatment paradigms for autoimmune diseases through innovative in vivo approaches.
